Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
PubMed PMID: 12399158
thereby interrupting DNA synthesis and inhibiting tumor cell growth
PubMed PMID: 23802098
8 nM in isolated enzyme assay and 101 nM in human whole blood
Naloxegol Oxalate
Canagliflozin - CAS# 842133-18-0 Catalog No.:M10730-10 PubMed PMID: 12399158Canagliflozin (INN, trade name Invokana) is a drug for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is an inhibitor of subtype 2 sodium glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the